We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IgA nephropathy

News List

What is the Confidence of this Pharmaceutical Company To Target its Sales Peak of CNY 10 Billion? Xiaobin/PharmaSources
August 07, 2023
Recently, at Everest Medicines' investor exchange activities, the management led by CEO Luo Yongqing put forward the target of "realizing the marketing of four commercial products in a short time, with a sales peak of CNY 10 billion".
FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease FDA
December 16, 2021
FDA has granted accelerated approval for Tarpeyo (budesonide) delayed release capsules to reduce proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression.
Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy americanpharmaceuticalreview
January 21, 2019
Omeros has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA).....